anti-PD-1 therapy

DRUG2 trials

Sponsors

University of Wisconsin, Madison, Novita Pharmaceuticals, Inc.

Conditions

Advanced or Metastatic Solid Tumor MalignanciesHead and Neck Cancer

Phase 1

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

Active, not recruitingNCT05023486

Novita Pharmaceuticals, Inc.Advanced or Metastatic Solid Tumor Malignancies

Start: 2021-12-07End: 2026-06-30Updated: 2026-04-14

Phase 2

Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma

TerminatedNCT04936841

University of Wisconsin, MadisonHead and Neck Cancer

Start: 2021-08-05End: 2022-10-04Updated: 2024-04-04

Related Papers

Activity of NP-G2-044 (fascin inhibitor) + anti–PD-1 in ICI-resistant advanced/metastatic solid tumors with expansion in cutaneous squamous cell carcinoma (CSCC).

Journal of Clinical Oncology2026-05-28

Durable responses in ICI-refractory or acquired resistance: Phase 2 study of NP-G2-044 combined with anti-PD-1 therapy.

Journal of Clinical Oncology2025-05-28

A phase 2 clinical trial of first-in-class fascin inhibitor NP-G2-044 as monotherapy and in combination therapy with anti-PD-1 immunotherapy in patients with advanced solid tumor malignancies.

Journal of Clinical Oncology2024-06-013 citations

Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer

Future Oncology2023-05-185 citations